Evaluation of Factors Affecting Survival and Chemotherapy Regimens in Patients with Gastric Cancer

Background/Purpose: The aim of our study was to examine the factors that affect the prognosis of gastric cancer and to evaluate the effect of different chemotherapy regimens on disease-free survival and overall survival. Methods: This cohort study retrospectively analyzed patients diagnosed with gastric cancer at our institution between 2009 and 2013. The demographic characteristics of the patients, the presence of Helicobacter pylori (HP), and the disease-free and overall survival according to the patients' treatment protocols were examined. Results: Thirty-three women and 85 men with a mean age of 58.6 ± 10.3 years were included in this study. %41 of the patients received 5-fluouracil, leukoverine chemotherapy (MAYO regimen), 26.2% docetaxel, cisplatin and fluorouracil combination (DCF regimen), 10.7% Epirubicin, cisplatin and Fluorouracil (ECF regimen), and 6.6% Cisplatin-Xeloda regimen. The average disease-free survival was 14.7 ± 11.1 months, and overall survival time was 16.5 ± 11.4 months. Disease-free survival and overall survival were longer in the MAYO regimen group compared to the combination chemotherapy groups (p <0.001). On multivariate analysis, metastasis and TNM stage were independent negative prognostic factors for disease-free and overall survival. Conclusion: Our study showed that disease-free and overall survival rates are quite low in advanced tumors and in patients with metastases at diagnosis, and revealed the limited effect of chemotherapy protocols, especially in this group of patients. However, the Mayo regimen was superior to other treatment protocols.